Ultimovacs ASA: Annual Report 2023

Oslo, 21 March 2024: Ultimovacs ASA (“Ultimovacs”, ticker ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces that the Board of Directors of Ultimovacs ASA has approved the Annual Report and ESG Report for 2023.

Please find a PDF version of the annual report, as well as the report in European Single Electronic Format (ESEF), as attachments to this release. The Annual Report is also available at the company's website: www.ultimovacs.com

This information is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act.

For further information, please see www.ultimovacs.com or contact:

Jónas Einarsson, Chairman of the Board of Directors of Ultimovacs ASA

Email: [email protected]

Phone: +47 480 96 355

Carlos de Sousa, CEO

Email: [email protected]

Phone: +47 908 92507

        

Hans Vassgård Eid, CFO

Email: [email protected]

Phone: +47 482 48632

Anne Worsøe, Head of Investor Relations & ESG

Email: [email protected]

Phone: +47 90686815

 

 

Attachments

• Ultimovacs-Annual-Report-2023
• UltimovacsASA-2023-12-31-en

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• XT Exchange Introduces XT Pay, Connecting USDT Balances With Local QR Payments
• Luvs Is Helping Parents With Affordable Diapers That Actually Work
• Best Meme Coin To Buy Today: Super Cat Posted a 750% Surge, but AlphaPepe Still Offers Entry Before Exchange Trading